Structured Review

Genentech anti vegf antibody
Ocular and systemic consequences of intravitreally injected <t>anti-VEGF</t> antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal <t>neovascularization</t> in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Anti Vegf Antibody, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti vegf antibody/product/Genentech
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti vegf antibody - by Bioz Stars, 2021-03
86/100 stars

Images

1) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

2) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

3) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

4) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

5) Product Images from "Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy"

Article Title: Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy

Journal: Oncotarget

doi: 10.18632/oncotarget.20410

AC708 reduces tumor burden in setting of adaptive resistance to anti-VEGF therapy Bioluminescent signal differences between B20 resistant mice with and without the addition of AC708 are shown. Automatic exposure time was used A. . Tumor weight, tumor nodules, and volume of ascites B. - D. are shown in IG10 murine ovarian cancer model of adaptive resistance treated with AC708, B20, or the combination, after resistance was determined by bioluminescent imaging. E. demonstrates bioluminescence imaging differences in those mice sensitive versus resistant to treatment with bevacizumab and paclitaxel in OVCAR432 HGSC model. Automatic exposure was time was used. Tumor weight of the OVCAR432 model shown in groups resistant to bevacizumab, plus paclitaxel, with and without AC708 F. . G. Quantification of macrophages from IG10 model treated with AC708, B20, or the combination in the setting of adaptive resistance. Macrophage content was determined by the percentage of CD11b + /F4/80 + cells out of CD45 + cells, using flow cytometry. The same groups were also stained for F4/80 via immunohistochemistry to quantify macrophages H. . **** denotes p≤0.0001.
Figure Legend Snippet: AC708 reduces tumor burden in setting of adaptive resistance to anti-VEGF therapy Bioluminescent signal differences between B20 resistant mice with and without the addition of AC708 are shown. Automatic exposure time was used A. . Tumor weight, tumor nodules, and volume of ascites B. - D. are shown in IG10 murine ovarian cancer model of adaptive resistance treated with AC708, B20, or the combination, after resistance was determined by bioluminescent imaging. E. demonstrates bioluminescence imaging differences in those mice sensitive versus resistant to treatment with bevacizumab and paclitaxel in OVCAR432 HGSC model. Automatic exposure was time was used. Tumor weight of the OVCAR432 model shown in groups resistant to bevacizumab, plus paclitaxel, with and without AC708 F. . G. Quantification of macrophages from IG10 model treated with AC708, B20, or the combination in the setting of adaptive resistance. Macrophage content was determined by the percentage of CD11b + /F4/80 + cells out of CD45 + cells, using flow cytometry. The same groups were also stained for F4/80 via immunohistochemistry to quantify macrophages H. . **** denotes p≤0.0001.

Techniques Used: Mouse Assay, Imaging, Flow Cytometry, Cytometry, Staining, Immunohistochemistry

6) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

7) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

8) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

9) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

10) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

11) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

12) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

13) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

14) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

15) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P
Figure Legend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

Techniques Used: Injection, Mouse Assay, Staining

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

16) Product Images from "Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Journal: PLoS ONE

doi: 10.1371/journal.pone.0134308

Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
Figure Legend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

Techniques Used: Injection, Staining, Two Tailed Test

Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P
Figure Legend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

Techniques Used: Injection, Mouse Assay, Staining, Expressing

Related Articles

Recombinant:

Article Title: PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
Article Snippet: .. Cells were treated with recombinant human PDGF-AA (100 ng/ml, Peprotech, 100-13 A), PDGF-AB (100 ng/ml, Peprotech, 100-00AB), PDGF-BB (100 ng/ml, Peprotech, 100-14B), Ki8751 (3 nM, Bio-Techne, 228559-41-9), crenolanib (5 nM, ChemieTek, CP-868596), anti-VEGF antibody B20 (10 μg/ml, Genentech), anti-PDGF-AA (10 μg/ml, Millipore, 07-1436), anti-PDGF-BB (10 μg/ml, Millipore, 07-1437), or control rabbit IgG (10 µg/ml, Cell Signaling, 2729). .. Human brain microvascular ECs were treated with glioma-CM for 2 days.

other:

Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice
Article Snippet: Anti-VEGF, anti-VEGF antibody.

Article Title: Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies
Article Snippet: Lastly, the results for the three different anti-VEGFs were taken together as a whole.

Mouse Assay:

Article Title: Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab
Article Snippet: Injections were performed from day 4 to 11 post tumor implantation. .. NP tumor implanted mice were treated with mouse anti-VEGF antibody (Genentech #5563) on days −1, 2, 5, 8, 11, 14, and 17 at a dose of 40 mg/kg i.p. .. Five days post implantation, Tie2-TK mice were irradiated with 20 Gy IR (2 Gy/day for 10 days).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Genentech anti vegf antibody
    Long-term effects of intravitreally injected <t>anti-VEGF</t> antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal <t>PBS</t> injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).
    Anti Vegf Antibody, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti vegf antibody/product/Genentech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti vegf antibody - by Bioz Stars, 2021-03
    86/100 stars
      Buy from Supplier

    86
    Genentech anti vegf agents ranibizumab
    (A) Phagocytosis in senescent retinal pigment epithelial (RPE) cells. Senescent RPE cells were treated with photoreceptor outer segments for 6 hours. Intracellular rhodopsin (red) was detected by immunocytochemistry. The red fluorescence crossing the cell membrane consisted primarily of debris remaining on the cell surface after washing. No difference in the number of rhodopsin positive cells was observed between naïve senescent RPE cells and anti-vascular endothelial growth factor-treated senescent RPE cells. (B) Percentages of rhodopsin-phagocytosing senescent RPE cells. ns = non-specific; sen = senescence; ran = <t>ranibizumab;</t> bev = bevacizumab; afl = aflibercept.
    Anti Vegf Agents Ranibizumab, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti vegf agents ranibizumab/product/Genentech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti vegf agents ranibizumab - by Bioz Stars, 2021-03
    86/100 stars
      Buy from Supplier

    86
    Genentech vegf a blocking antibody
    Effect of <t>VEGF‐A</t> blocking treatment on tumor volume. Shb+/+RT or Shb+/−RT mice were treated with PBS (PBS) or VEGF‐A blocking antibody (ab) during weeks 10–12. Tumors were collagenase isolated and classified as “red” or “white” according to the insert. Tumor volumes were estimated and given as means ± SEM. n = 13 for +/+ PBS; n = 14 for +/− PBS; n = 10 for +/+ ab; n = 11 for +/− ab. * p
    Vegf A Blocking Antibody, supplied by Genentech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf a blocking antibody/product/Genentech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf a blocking antibody - by Bioz Stars, 2021-03
    86/100 stars
      Buy from Supplier

    Image Search Results


    Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

    Journal: PLoS ONE

    Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

    doi: 10.1371/journal.pone.0134308

    Figure Lengend Snippet: Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Quantitative analyses of the number of large lipid droplets ( > 50 μm 2 ) per field at x400 magnification ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Quantitative analyses of vascularity of interscapular BAT demonstrated by isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (C) The changes in body weight from P14 to P56. Anti-VEGF, anti-VEGF antibody. NS , not significant (two-tailed, unpaired T-test).

    Article Snippet: To estimate the level of anti-VEGF antibody using goat IgG ELISA, we utilized PBS as the control.

    Techniques: Injection, Staining, Two Tailed Test

    Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

    Journal: PLoS ONE

    Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

    doi: 10.1371/journal.pone.0134308

    Figure Lengend Snippet: Ocular and systemic consequences of intravitreally injected anti-VEGF antibody. (A) Effects of intravitreally injected anti-VEGF antibody (1 μg/eye) on retinal neovascularization in OIR mice ( n = 6). Neovascular tufts were highlighted with yellow pseudocolor on representative images of isolectin B4-stained retina. The area of neovascular tufts was normalized to total retinal area; then, the effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). Scale bar, 200 μm. (B) Retinal VEGF concentrations at P17 with intravitreal injection of PBS or anti-VEGF antibody ( n = 3). The level of VEGF was normalized to total amounts of proteins in the retina. (C) Serum concentrations of anti-VEGF antibody after intravitreal injection at P14, P17, and P21 ( n = 3–6). (D) Serum VEGF concentrations after intravitreal injection of anti-VEGF antibody at P17, P21, and P28 ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS , not significant; **, P

    Article Snippet: To estimate the level of anti-VEGF antibody using goat IgG ELISA, we utilized PBS as the control.

    Techniques: Injection, Mouse Assay, Staining

    Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

    Journal: PLoS ONE

    Article Title: Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

    doi: 10.1371/journal.pone.0134308

    Figure Lengend Snippet: Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Concentrations of VEGF in interscapular BAT at P21 and P28. The level of VEGF was normalized to total amounts of proteins in BAT ( n = 3–6). (B) Representative images of H E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody show enlarged lipid droplets. Scale bar, 20 μm. (C) Quantitative analyses of vascularity of interscapular BAT based on isolectin B4 staining ( n = 3–6). The effects of anti-VEGF antibody were quantified and normalized to the control (intravitreal PBS injection). (D) Relative expression of Ucp1 and Ppargc1a in interscapular BAT ( n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *, P

    Article Snippet: To estimate the level of anti-VEGF antibody using goat IgG ELISA, we utilized PBS as the control.

    Techniques: Injection, Mouse Assay, Staining, Expressing

    (A) Phagocytosis in senescent retinal pigment epithelial (RPE) cells. Senescent RPE cells were treated with photoreceptor outer segments for 6 hours. Intracellular rhodopsin (red) was detected by immunocytochemistry. The red fluorescence crossing the cell membrane consisted primarily of debris remaining on the cell surface after washing. No difference in the number of rhodopsin positive cells was observed between naïve senescent RPE cells and anti-vascular endothelial growth factor-treated senescent RPE cells. (B) Percentages of rhodopsin-phagocytosing senescent RPE cells. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept.

    Journal: Korean Journal of Ophthalmology : KJO

    Article Title: Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells

    doi: 10.3341/kjo.2017.0079

    Figure Lengend Snippet: (A) Phagocytosis in senescent retinal pigment epithelial (RPE) cells. Senescent RPE cells were treated with photoreceptor outer segments for 6 hours. Intracellular rhodopsin (red) was detected by immunocytochemistry. The red fluorescence crossing the cell membrane consisted primarily of debris remaining on the cell surface after washing. No difference in the number of rhodopsin positive cells was observed between naïve senescent RPE cells and anti-vascular endothelial growth factor-treated senescent RPE cells. (B) Percentages of rhodopsin-phagocytosing senescent RPE cells. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept.

    Article Snippet: The percentages of SA-β-gal-positive RPE cells were not significantly different after treatment with the anti-VEGF agents ranibizumab, bevacizumab, and aflibercept were 78.8 ± 7.08%, 83.7 ± 5.78%, and 76.2 ± 6.45%, respectively (all comparisons, p > 0.05) ( ).

    Techniques: Immunocytochemistry, Fluorescence

    (A) The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining of senescent retinal pigment epithelial (RPE) cells treated with anti-vascular endothelial growth factor (VEGF) agents. There was no significant increase in TUNEL-positive cells among senescent RPE cells treated with anti-VEGF agents. (B) Percentage of TUNEL-positive senescent RPE cells. (C) The viability of senescent RPE cells treated with anti-VEGF agents was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. (D) The change in pigmentation of senescent RPE cells was evaluated after anti-VEGF treatment. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. * p

    Journal: Korean Journal of Ophthalmology : KJO

    Article Title: Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells

    doi: 10.3341/kjo.2017.0079

    Figure Lengend Snippet: (A) The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining of senescent retinal pigment epithelial (RPE) cells treated with anti-vascular endothelial growth factor (VEGF) agents. There was no significant increase in TUNEL-positive cells among senescent RPE cells treated with anti-VEGF agents. (B) Percentage of TUNEL-positive senescent RPE cells. (C) The viability of senescent RPE cells treated with anti-VEGF agents was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. (D) The change in pigmentation of senescent RPE cells was evaluated after anti-VEGF treatment. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. * p

    Article Snippet: The percentages of SA-β-gal-positive RPE cells were not significantly different after treatment with the anti-VEGF agents ranibizumab, bevacizumab, and aflibercept were 78.8 ± 7.08%, 83.7 ± 5.78%, and 76.2 ± 6.45%, respectively (all comparisons, p > 0.05) ( ).

    Techniques: TUNEL Assay, Staining

    (A) Proliferation of senescent retinal pigment epithelial (RPE) cells treated with anti-vascular endothelial growth factor agents were evaluated using the 5-ethynyl-2-deoxyuridine (EdU) assay. Red dots (EdU-positive cells) represent proliferating RPE cells. (B) Percentage of EdU-positive senescent RPE cells. There were no differences in cell proliferation between naïve senescent RPE cells and anti-vascular endothelial growth factor-treated senescent RPE cells. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. Bar = 200 µm.

    Journal: Korean Journal of Ophthalmology : KJO

    Article Title: Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells

    doi: 10.3341/kjo.2017.0079

    Figure Lengend Snippet: (A) Proliferation of senescent retinal pigment epithelial (RPE) cells treated with anti-vascular endothelial growth factor agents were evaluated using the 5-ethynyl-2-deoxyuridine (EdU) assay. Red dots (EdU-positive cells) represent proliferating RPE cells. (B) Percentage of EdU-positive senescent RPE cells. There were no differences in cell proliferation between naïve senescent RPE cells and anti-vascular endothelial growth factor-treated senescent RPE cells. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. Bar = 200 µm.

    Article Snippet: The percentages of SA-β-gal-positive RPE cells were not significantly different after treatment with the anti-VEGF agents ranibizumab, bevacizumab, and aflibercept were 78.8 ± 7.08%, 83.7 ± 5.78%, and 76.2 ± 6.45%, respectively (all comparisons, p > 0.05) ( ).

    Techniques: EdU Assay

    (A) Effects of anti-vascular endothelial growth factor treatment on senescence of retinal pigment epithelial (RPE) cells. (B) Percentage of senescence-associated-β-galactosidase (SA-β-gal) positive senescent RPE cells. Anti-vascular endothelial growth factor treatment did not cause additional senescence of RPE cells. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. Bar = 200 µm.

    Journal: Korean Journal of Ophthalmology : KJO

    Article Title: Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells

    doi: 10.3341/kjo.2017.0079

    Figure Lengend Snippet: (A) Effects of anti-vascular endothelial growth factor treatment on senescence of retinal pigment epithelial (RPE) cells. (B) Percentage of senescence-associated-β-galactosidase (SA-β-gal) positive senescent RPE cells. Anti-vascular endothelial growth factor treatment did not cause additional senescence of RPE cells. ns = non-specific; sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. Bar = 200 µm.

    Article Snippet: The percentages of SA-β-gal-positive RPE cells were not significantly different after treatment with the anti-VEGF agents ranibizumab, bevacizumab, and aflibercept were 78.8 ± 7.08%, 83.7 ± 5.78%, and 76.2 ± 6.45%, respectively (all comparisons, p > 0.05) ( ).

    Techniques:

    (A) Immunofluorescence staining for zonula occludens-1 (ZO-1). (B) Immunofluorescence staining for RPE65. ZO-1 and RPE65 proteins were uniformly expressed regardless of whether senescent retinal pigment epithelial (RPE) cells were treated with anti-vascular endothelial growth factor agents. (C) Western blot assay for the expression of ZO-1 and RPE65 in senescent RPE cells treated with each of anti-vascular endothelial growth factor agents. sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. Bar = 200 µm.

    Journal: Korean Journal of Ophthalmology : KJO

    Article Title: Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells

    doi: 10.3341/kjo.2017.0079

    Figure Lengend Snippet: (A) Immunofluorescence staining for zonula occludens-1 (ZO-1). (B) Immunofluorescence staining for RPE65. ZO-1 and RPE65 proteins were uniformly expressed regardless of whether senescent retinal pigment epithelial (RPE) cells were treated with anti-vascular endothelial growth factor agents. (C) Western blot assay for the expression of ZO-1 and RPE65 in senescent RPE cells treated with each of anti-vascular endothelial growth factor agents. sen = senescence; ran = ranibizumab; bev = bevacizumab; afl = aflibercept. Bar = 200 µm.

    Article Snippet: The percentages of SA-β-gal-positive RPE cells were not significantly different after treatment with the anti-VEGF agents ranibizumab, bevacizumab, and aflibercept were 78.8 ± 7.08%, 83.7 ± 5.78%, and 76.2 ± 6.45%, respectively (all comparisons, p > 0.05) ( ).

    Techniques: Immunofluorescence, Staining, Western Blot, Expressing

    Effect of VEGF‐A blocking treatment on tumor volume. Shb+/+RT or Shb+/−RT mice were treated with PBS (PBS) or VEGF‐A blocking antibody (ab) during weeks 10–12. Tumors were collagenase isolated and classified as “red” or “white” according to the insert. Tumor volumes were estimated and given as means ± SEM. n = 13 for +/+ PBS; n = 14 for +/− PBS; n = 10 for +/+ ab; n = 11 for +/− ab. * p

    Journal: Molecular Oncology

    Article Title: Heterogeneity among RIP-Tag2 insulinomas allows vascular endothelial growth factor-A independent tumor expansion as revealed by studies in Shb mutant mice: Implications for tumor angiogenesis

    doi: 10.1016/j.molonc.2012.01.006

    Figure Lengend Snippet: Effect of VEGF‐A blocking treatment on tumor volume. Shb+/+RT or Shb+/−RT mice were treated with PBS (PBS) or VEGF‐A blocking antibody (ab) during weeks 10–12. Tumors were collagenase isolated and classified as “red” or “white” according to the insert. Tumor volumes were estimated and given as means ± SEM. n = 13 for +/+ PBS; n = 14 for +/− PBS; n = 10 for +/+ ab; n = 11 for +/− ab. * p

    Article Snippet: The VEGF‐A blocking antibody (B20‐4.1.1 anti‐VEGF mAB) was kindly provided by Genentech.

    Techniques: Blocking Assay, Mouse Assay, Isolation